Docetaxel in the treatment of hormone-resistant prostate cancer
https://doi.org/10.17650/1726-9776-2007-3-1-50-52
Abstract
Docetaxel is the most effective chemical agent used in the treatment of hormone-resistant prostate cancer (HRPC). Three different docetaxel-based combinations were tested. The study included 30 patients with HRPC: 10 patients received chemotherapy as intravenous docetaxel, 75 mg/m2 once every 21 days with prednisolone, 10 mg/day (DP); other 10 patients had docetaxel, 75 mg/m2, estramustin, 300 mg/m2 daily, and prednisolone, 10 mg daily (DEP); 10 more patients received a combination of doxorubicin, 20 mg/m2 on day 1 of weeks 1, 3, and 5, ketoconazole, 1200 mg/day on days 1—7 of weeks 1, 3, and 5, docetaxel, 20 mg/m2 on day 1 of weeks 2, 4, and 6, estramustin, 420 mg/day on days 1—7 of weeks 2, 4, and 6, prednisolone, 10 mg daily (DEKP). The study revealed that all these three combinations have about the same efficacy; with their use, the clinical improvement rate was 70—80%. Thus, the use of docetaxel in different combinations is an effective treatment for HRPC.
About the Authors
B. V. Bukharkin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Urology
Russian Federation
Department of Urology
S. A. Kalinin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Department of Urology
Russian Federation
Department of Urology
References
1. Graft N., Shostac Y., Carey M. et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999;5(3):280—5.
2. Green S., Furr B. Prospects for the treatment of endocrine-responsive tumors. Endocr Relat Cancer1999;6(3):349—71.
3. Lein M., Yung K., Dinh L.K. et al. Synthetic inhibitor of metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 2000;43(2):77—82.
4. Petrylak D.P. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54:30—5.
5. Primo L.N., Meyers F.K. Treatment options in androgen-independent prostate cancer. Cancer Invest 1999;17(2):137—44.
6. Rosenthal M.A. Advances in the management of prostate cancer. Aust NZJ Med 2000;30(5):593—9.
7. Eisenberger M.A., De Vit R., Berry W. et al. A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormonerefractory prostate cancer. Proc Am Soc Clin Oncol 2004;45:5 (abstr. 4).
8. Petrylak D.P., Tangen C., Hussain M. et al. SWOG 99-16: Randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednizolone in men with androgen independent prostate cancer. Proc Am Soc Clin Oncol 2004;45:5 (abstr. 3).
9. Ellerhorst J.A., Tu S.M., Amato R.J. et al. Phase II trial of alternating weekly chemogormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997;3:2371—6.
Review
For citations:
Bukharkin B.V., Kalinin S.A. Docetaxel in the treatment of hormone-resistant prostate cancer. Cancer Urology. 2007;3(1):50-52. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-1-50-52
Views:
285
Email this article 